Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response

Junho Kang(Ulsan College), Changhoon Yoo(Ulsan College), Dae Wook Hwang(Asan Medical Center), Kyu‐pyo Kim(Ulsan College), Baek‐Yeol Ryoo(Asan Medical Center), Shin Hwang(Asan Medical Center), Seung‐Mo Hong(Ulsan College), Song Cheol Kim(Ulsan College), Tae Jun Song, Ki‐Hun Kim(Pusan National University Hospital), Sang Soo Lee(Chungbuk National University Hospital), Jin‐hong Park, Jae Ho Jeong(Ulsan College), Dongwook Oh(Ulsan College), Hee-Sang Hwang(Ulsan College), Do Hyun Park(Massachusetts Institute of Technology)
Cancer Research and Treatment
December 18, 2019
10.4143/crt.2019.493
Cited by 71

Related Papers

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577